Science

Scientific Publications

55.	Cohen S, Barer F, Itzhak I, Silverman MH, Fishman P. Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson. J Immunol Res. 2018 May 15;2018:2310970
54.	Ohana G, Cohen S, Rath-Wolfson L, Fishman P. A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomy. Mol Med Rep. 2016 Nov;14(5):4335-4341
53.	David M, Gospodinov DK, Gheorghe N, Mateev GS, Rusinova MV, Hristakieva E, Solovastru LG, Patel RV, Giurcaneanu C, Hitova MC, Purcaru AI, Horia B, Tsingov II, Yankova RK, Kadurina MI, Ramon M, Rotaru M, Simionescu O, Benea V, Demerdjieva ZV, Cosgarea MR, Morariu HS, Michael Z, Cristodor P, Nica C, Silverman MH, Bristol DR, Harpaz Z, Farbstein M, Cohen S, Fishman P. Treatment of Plaque-Type Psoriasis With Oral CF101: Data from a Phase II/III Multicenter, Randomized, Controlled Trial. J Drugs Dermatol. 15(8):931-8
52.	Fishman P and Cohen S. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis. Clin Rheumatol, 2016; 35(9):2359-62
51.	Rumen M Stoilov, Rodina N Licheva, Mariyana K Mihaylova, Tatiana Reitblat, Emil A Dimitrov, Krasimira M Shimbova, Girish Bhatia, Ameet Pispati, Alexandra Gurman- Balbir, BR Bagaria, Boytcho Aleksandrov Oparanov, Sari Fishman, Zivit Harpaz, Motti Farbstein, Shira Cohen, David Bristol, Michael H Silverman and Pnina Fishman. Therapeutic Effect of Oral CF101 in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled Phase II Study. Immunome Res 2014, 11:1
50.	Pnina Fishman. Adenosine Receptors – The Promise of A3AR Research. Drug Development & Delivery March, 2015 Vol 15 No 1
49.	Cohen S, Barer F, Bar-Yehuda S, IJzerman AP, Jacobson KA, Fishman P. A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action. Mediators Inflamm. 2014;2014:708746. doi: 10.1155/2014/708746. Epub 2014 Oct 13
48.	Pnina Fishman, Shira Cohen, Sara Bar Yehuda. Targeting the A3 adenosine receptor for glaucoma treatment (Review). Molecular Medicine Reports. DOI: 10.3892/mmr.2013.1413
47.	Stemmer M, Benjaminov F, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, Cohen S, Patoka R, Singer B, Kerns WD, Fishman P. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study. The Oncologist. 18:25-26, 2013 Online version
46.	Pnina Fishman, Sara Bar-Yehuda, Bruce T. Liang and Kenneth A. Jacobson. Pharmacological and therapeutic effects of A3 adenosine receptor agonists. Drug Discov Today. 2012;17(7-8):359-66
45.	Clara C. Blad, Jacobien K. von Frijtag Drabbe Künzel, Henk de Vries, Thea Mulder-Krieger, Sara Bar-Yehuda, Pnina Fishman, Adriaan P. IJzerman. Putative role of the adenosine A3 receptor in the antiproliferative action of N6-(2-isopentenyl)adenosine. Purinergic Signal, 2011
44.	Sara Bar-Yehuda, Dror Luger, Avivit Ochaion, Shira Cohen, Renana Patokaa, Galina Zozulya, Phyllis B. Silver, Jose Maria Garcia Ruiz De Morales, Rachel R. Caspi, Pnina Fishman. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101. Int J Mol Med. Nov;28(5):727-3, 2011
43.	Ashar JN, Mathur A, Sangwan V. Avni I, Sliverman MH, Bar Yehuda S, Fishman P. CF101 for dry eye. Ophthalmology. 118:1011-1012, 2011
42.	David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky, Yankova R, Kouzeva V, Ramon M, Silverman MH, Fishman P. Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. Journal of the European Academy of Dermatology and Venereology, 2011
41.	Cohen S, Stemmer SM,Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, Fishman P. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. Journal of Cellular Physiology, 226:2438-2447, 2011
40.	I. Avni, H. Garzozi, I. Barequet, F. Segev, D. Varssano, G. Sartani, N. Chetrit, E. Bakshi, D. Zadok, O. Tomkins, G. Litvin, K. Jacobson, S Fishman, Z. Harpaz, M. Farbstein, S. Bar Yehuda, M. Silverman, W. Kerns, D. Bristol, I Cohn, P. Fishman. Treatment of Dry Eye Syndrome with Orally Administered CF101. Data from a Phase 2 Clinical Trial. Ophthalmology , 117:1287-1293, 2010
39.	Fishman, P., Bar-Yehuda, S., Varani, K., Gessi, S., Merighi, S., and Borea, PA. Agonists and Antagonists: Molecular Mechanisms and Therapeutic Applications. In: P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics. © Springer Science+Business Media B.V. 2010
38.	Fishman, P., Bar-Yehuda, S. Rheumatoid Arthritis: History, Molecular Mechanisms and Therapeutic Applications. P.A. Borea (ed.), A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics. © Springer Science+Business Media B.V. 2010
37.	S. Bar-Yehuda, L. Rath-Wolfson, L. Del Valle, A. Ochaion, S. Cohen, R. Patoka, G. Zozulya, F. Barer, E. Atar, S. Pina-Oviedo, G. Perez-Liz, D. Castel, and P. Fishman. Induction of an Antiinflammatory Effect and Prevention of Cartilage Damage in at Knee Osteoarthritis by CF101 Treatment. ARTHRITIS & RHEUMATISM Vol. 60, No. 10, (2009) 3061–3071
36.	P. Fishman, S. Bar-Yehuda, M. Synowitz, J.D. Powell, K.N. Klotz, S. Gessi, and P.A. Borea. Adenosine Receptors and Cancer. Handbook of Experimental Pharmacology 193 (2009) 399-441
35.	A. Ochaion, S. Bar-Yehuda, S. Cohen, F. Barer, R. Patoka, H. Amital, T. Reitblat, A. Reitblat, J. Ophir, I. Konfino, Y. Chowers, S. Ben-Horin, P. Fishman. The anti-inflammatory target A3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn’s disease. Cellular Immunology 258 (2009) 115–122
34.	Bar-Yehuda S., Stemmer S.M., Madi L., Castel D., Ochaion A., Cohen S., Barer F., Zabutti A., Perez-Liz G., Del Valle L., Fishman P. The A3 adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kB signal transduction pathways. Int J Onc 33: 287-295, 2008
33.	Ochaion A., Bar-Yehuda S., Cohen S., Amital H., Jacobson K.A., Joshi B.V., Gao Z.G., Barer F., Patoka R., Del Valle L., Perez-Liz G., Fishman P. The A3 Adenosine Receptor Agonist CF502 Inhibits the PI3K, PKB/Akt and NF-kB Signaling Pathway in Synoviocytes from Rheumatoid Arthritis Patients and in Adjuvant Induced Arthritis Rats
32.	Silverman M. H., Strand V., Markovits D., Nahir M., Reitblat T., Molad Y., Rosner I, Rozenbaum M., Mader R., Adawi M., Caspi D., Tishler M., Langevitz P., Rubinow A., Friedman J., Green L., Tanay A., Ochaion A., Cohen S., Kerns W. D., Cohn I., Fishman-Furman S., Farbstein M., Bar-Yehuda S., Fishman P. Clinical Evidence for Utilization of the A3 Adenosine Receptor as a Target to Treat Rheumatoid Arthritis: Data from a Phase II Clinical Trial. The Journal of Rheumatology 2008; 35:1.
31.	Bar Yehuda S., Silvermen M., Kerns W., Ochaion, A., Cohen, S., Fishman, P. The Anti-inflammatory Effect of A3 Adenosine Receptor Agonists: A Novel Targeted Therapy for Rheumatoid Arthritis. Expert Opin. Investig. Drugs (2007) 16(10):1601-1613.
30.	Fishman P., Jacobson KA., Ochaion A., Cohen S., Bar Yehuda S. The Anti-Cancer Effect of A3 Adenosine Receptor Agonists: A Novel Targeted Therapy. Immun, Endoc. & Metab. Agents in Med. Chem. 7:298-303, 2007.
29.	Madi L., Cohn, S. Ochaion A., Bar-Yehuda S., Barer F., Fishman P. Over-expression of A3 Adenosine Receptor in PBMNC of Rheumatoid Arthritis Patients: Involvement of NF-kB in mediating Receptor Level. J. Rheumatology. 34:20-26, 2007.
28.	Fishman, P., Bar-Yehuda, S., Madi, L. In: Adenosine, Tumors, and Immunity. ADENOSINE RECEPTORS: Therapeutic Aspects for Inflammatory and Immune Diseases. Hasko, G., Cronstein, BN., Szabo, C., Ed.: Taylor&Francis; London. P: 299-312, 2007
27.	Ochaion A, Bar-Yehuda S, Cohn S, Del Valle L, Perez-Liz G, Madi L, Barer F, Farbstein M, Fishman-Furman S, Reitblat T, Reitblat A, Amital H, Levi Y, Molad Y, Mader R, Tishler M, Langevitz P, Zabutti A, Pnina Fishman. Methotrexate enhances the anti-inflammatory effect of CF101 via upregulation of the A3 adenosine receptor expression. Arthritis Research & Therapy 2006, 8:R169.
26.	Rath-Wolfson L., Bar-Yehuda S. Madi L., Fishman P. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. Clin Exp Rheumatol. 2006; 24(4):400-6.
25.	Fishman P., Bar-Yehuda S., Madi L., Rath-Wolfson L., Ochaion A., Cohen S. and Baharav E. The PI3K-NF-kB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant induced arthritis. Arthritis Research & Therapy 2006, 8:R33.
24.	Bar-Yehuda, S., Madi,L., Silberman, D., Slosman G., Shkapenuk, M., Fishman, P. CF101, an Agonist to the A3 Adenosine Receptor Enhances the Chemotherapeutic Effect of 5-Flurouracil in a Colon Carcinoma Murine Model. Neoplasia. 7:85-90. 2005.
23.	Baharav, E., Bar-Yehuda, S., Madi, L., Silberman, D., Rath-Wolfson, L., Halpren, M., Ochaion, A., Weinberger, A., Fishman, P. The Anti-inflammatory Effect of A3 Adenosine Receptor Agonists in Murine Autoimmune Arthritis Models. J Rheumatol. 32:469-76. 2005.
22.	van Troostenburg, A. R., Clark, E. V., Carey, W. D. H., Warrington, S. J., Kerns, W.D., Cohn, I., Silverman, M. H., Bar-Yehuda, S., Fong, K.L. L., Fishman, P. Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther. 42: 534-42, 2004.
21.	Madi, L., Ochaion, A., Rath-Wolfson, L., Bar-Yehuda, S., Erlanger, A., Ohana, G., Harish, A., Merimski, O., Barer, F., Fishman, P. The A3 Adenosine Receptor is Highly Expressed in Tumor vs. Normal Cells: Potential Target for Tumor Growth Inhibition. Clinical Cancer Research, 10: 4472-4479, 2004.
20.	Fishman, P., Bar-Yehuda, S., Ohana, G., Ochaion, A., Engelberg, A., Barer, F., Madi, L. An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3ß and NF-kB. Oncogene, 23: 2465-2471, 2004.
19.	Harish, A., Ohana, G., Fishman, P., Arnon, O., Bar-Yehuda, S. A3 Adenosine Receptor Agonist Potentiates Natural Killer Cell Activity. International J Oncol, 23:1245-1249. 2003.
18.	Ohana, G., Bar-Yehuda, S., Arich, A., Madi L., Dreznick Z., Silberman D., Slosman G., Volfsson-Rath, L., Pnina Fishman. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. British J Cancer, 89: 1552-1558, 2003.
17.	Madi, L., Bar-Yehuda, S., Barer, F., Ardon, E., Ochaion, A., Fishman, P. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. JBC. 278:42121-42130, 2003.
16.	Fishman, P., Bar-Yehuda, S., Rath-Wolfson, L., Ardon, E., Barrer, F., Ochaion, A., Madi, L. Targeting the A3 adenosine receptor for cancer therapy: inhibition of Prostate carcinoma cell growth by A3AR agonist. Anticancer Res. 23:2077-2083, 2003.
15.	Merimsky O, Madi L, Bar-Yehuda S, Fishman P : Modulation of the A3 adenosine receptor by low agonist concentration induced anti-tumor and myelostimulation effects. Drug Dev Res. 58:386-389, 2003.
14.	Fishman, P., Bar-Yehuda, S. Pharmacology and therapeutic applications of A3 receptor subtype. Curr Top Med Chem. 3:463-469, 2003.
13.	Baharav, E., Dubrosin, A., Fishman, P., Bar-Yehuda, S., Halpern, M., Weinberger, A. Suppression of experimental zymosan induced arthritis by intraperitoneal administration of adenosine. Drug Dev Res. 57 :182-186, 2002.
12.	Bar-Yehuda, S., Madi, L., Barak, D., Mittelman, M., Ardon, E., Ochaion, A, Cohn, S., Fishman, P. Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. Exp Hematol. 30:1390-1398, 2002.
11.	Fishman, P., Bar-Yehuda, S., Madi, L., Cohn, I. A3 adenosine receptor as a target for cancer therapy. Anti-cancer Drugs. 13:437-443, 2002.
10.	Fishman, P., Madi, L., Bar-Yehuda, S., Barer, F., Del Valle, L., Khalili, K. Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. Oncogene 21:4060-4064, 2002.
9.	Fishman, P., Bar-Yehuda, S., Barer, F., Madi, L., Multani, A.F, Pathak, S. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res. 269: 230-236, 2001.
8.	Ohana, G., Bar-Yehuda, S, Barer, F., Fishman, P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol. 186: 19-23. 2001.
7.	Fishman, P., Bar-Yehuda, S., Farbstein, T., Barer, F., Ohana, G. Adenosine acts as a chemoprotective agent by stimulating G-CSF production: a role for A1 and A3 adenosine receptors. J Cell Physiol. 183: 393-398, 2000.
6.	Fishman, P., Bar-Yehuda, S., Ohana, G., Pathak, S., Wasserman, L., Barer, F., Multani, A.F. Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A3 adenosine receptor. Eur. J Cancer 36:1452-1458, 2000.
5.	Bar-Yehuda, S., Barer, F., Volfsson, L., Fishman, P. Resistance of muscles to tumor metastasis: a role for A3 adenosine receptor agonists. Neoplasia 3: 125-131, 2001.
4.	Bar-Yehuda, S., Farbstein, T., Barer, F., Ohana, G., Fishman, P. Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice. Clin. Exp. Metastasis 17:513-535, 1999.
3.	Fishman, P., Bar-Yehuda, S., Vagman, L. Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. Cancer Res. 58:3181-3187, 1998.
2.	Cohen-Aloro, D., Merimsky, O., Bar-Yehuda, S., Klein, B., Kayzer, S., Fishman, P. Mononuclear cells release low molecular weight factors with anti-cancer activity: A lower level of production by cells of cancer patients. Int. J Oncol. 12:921-925, 1998.
1.	Djaldetti, M., Sredni, B., Zigelman, R., Verber, M., Fishamn, P. Muscle cells produce a low molecular weight factor with anti-cancer activity. Clin Exp Metastasis 14:189-196, 1996.

Homepage \| Contact us	only canfite.com